Течение COVID-19 у лиц с сахарным диабетом и ожирением в кластере метаболического синдрома
Ключевые слова:
сахарный диабет, ожирение, метаболический синдром, COVID-19, патогенез
Аннотация
Пандемия новой коронавирусной инфекции COVID-19, вызванная вирусом SARS-CoV-2 является актуальнейшей проблемой как отечественного, так и мирового здравоохранения. На сегодня уже установлено, что при данной вирусной инфекции наиболее уязвимыми с выраженным тяжелым течением и высокой летальностью являются лица, имеющие различные хронические заболевания, в том числе сахарный диабет (СД) и ожирение, которые выступают основными компонентами метаболического синдрома (МС). В статье обсуждаются: эпидемиология, патогенез, наиболее распространенные симптомы заболевания, а также особенности течения COVID-19 у лиц с ожирением и СД.
Скачивания
Данные скачивания пока недоступны.
Литература
1. Бабенко А.Ю., Лаевская М.Ю. Сахарный диабет и COVID 19. Как они связаны? Современные стратегии борьбы. Артериальная гипертензия. 2020; 26(3):304–311. doi:10.18705/1607-419X-2020-26-3-304-311.
Babenko A.Yu., Laevskaya M.Yu. Diabetes mellitus and COVID 19. How are they related? Modern strategies of struggle. Arterial hypertension. 2020;26(3):304–311. doi:10.18705/1607-419X-2020-26-3-304-311. [In Russian]
2. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID 19 epidemic. Diabetes Metab Syndr. 2020;14(3):211–212. doi:10.1016/ j.dsx.2020.03.002.
3. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q. Prevalence of comorbidities and its effects in patients infected with SARSCoV 2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi:10.1016/j.ijid.2020.03.
4. Xue T, Li Q, Zhang Q, Lin W, Wen J, Li L et al. Blood glucose levels in elderly subjects with type 2 diabetes during COVID 19 outbreak: a retrospective study in a single center. medRxiv. 2020. [Рublished online 2 April 2020]. doi:10.1101/2020.03.31.20048579.
5. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis / B. Wang [et al.] // Aging (Albany NY). – 2020. – Vol. 12. – P. 6049-6057. URL: https://doi.org/10.18632/aging.103000.
6. Epidemiology Working Group for Ncip Epidemic Response. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. (In Chinese)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145−151.
7. CDC. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 − United States, February 12 − March 28, 2020. MMWR. 2020;69(13):382–386.
8. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. doi: https://doi.org/10.1001/jama.2020.4683.
9. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–310. doi: https://doi.org/10.1016/j.dsx.2020.04.004
10. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395–403. doi: https://doi.org/10.1016/j.dsx.2020.04.018.
11. Ling, L., Lianfeng, L., Wei, C., Taisheng, L. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia // Emerg Microbes Infect. – 2020. – Vol. 9(1). – P. 727-732. doi: 10.1080/22221751.2020.1746199.
12. Tang, N.L., Chan, P.K., Wong, C.K. et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome // Clin Chem. – 2005. – Vol. 51. – P. 2333–2340. doi:10.1373/clinchem.2005.054460.
13. Zhang, H., Penninger, J.M., Li, Y., Zhong, N., Slutsky, A. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target // Intensive Care Med. – 2020. – Vol. 46(4). – P. 586–590. doi: 10.1007/s00134-020-05985-9.
14. Wu, Z., McGoogan, J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention // JAMA. – 2020. doi.: 10.1001/jama.2020.2648.
15. Channappanavar, R., Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin Immunopathol. – 2017. – Vol. 39. – P. 529–539. doi: 10.10 07/s0 0281-017-0629-x.
16. Huang, C., Wang, Y., Li, X., Ren, L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. – 2020. – Vol. 395(10223), Feb 15. – P. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
17. Jing, Y., Zheng, Y. Gou, X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis // Int J Infect Dis. – 2020. – Mar 12. doi:10.1016/j.ijid.2020.03.017.
18. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome // Lancet Respir Med. – 2020. – Feb 18. doi:10.1016/S2213-260 0(20)30 076-X.
19. Rabi FA, Al Zoubi MS, Kasasbeh GA, et al. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231–235. doi: https://doi.org/10.3390/pathogens9030231
20. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine. 2020 Apr;68(1):2-5. doi: 10.1007/s12020-020-02294-5. PMID: 32279224; PMCID: PMC7150529.
21. Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020;16(6):297–298. doi.org/10.1038/s41574-020- 0353-9.
22. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid 19. N Engl J Med. 2020;382(17):1653–1659. doi.org/10.1056/NEJMsr2005760.
23. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–199. doi.org/10.1007/s00592-009- 0109-4.
24. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41(2):127–133.
25. Richard C, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. BMJ Open Diabetes Res Care. 2017;5(1): e000379. doi:10.1136/bmjdrc 2016-000379.
26. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
27. Richard C, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. BMJ Open Diabetes Res Care. 2017;5(1): e000379. doi:10.1136/bmjdrc 2016-000379.
28. Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc. 2017;14(Suppl. 5):S406–S409.
29. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020. [Ahead of print, published online 9 April 2020]. doi:10.1002/ oby.22831.
30. Kravchuk E.N, Neymark A.E, Babenko A.Yu, Grineva E.N. Obesity and COVID 19. Arterial’naya Gipertenziya = Arterial Hypertension. 2020;26(4):439–445. doi:10.18705/1607-419X-2020-26-4-440-446
Babenko A.Yu., Laevskaya M.Yu. Diabetes mellitus and COVID 19. How are they related? Modern strategies of struggle. Arterial hypertension. 2020;26(3):304–311. doi:10.18705/1607-419X-2020-26-3-304-311. [In Russian]
2. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID 19 epidemic. Diabetes Metab Syndr. 2020;14(3):211–212. doi:10.1016/ j.dsx.2020.03.002.
3. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q. Prevalence of comorbidities and its effects in patients infected with SARSCoV 2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi:10.1016/j.ijid.2020.03.
4. Xue T, Li Q, Zhang Q, Lin W, Wen J, Li L et al. Blood glucose levels in elderly subjects with type 2 diabetes during COVID 19 outbreak: a retrospective study in a single center. medRxiv. 2020. [Рublished online 2 April 2020]. doi:10.1101/2020.03.31.20048579.
5. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis / B. Wang [et al.] // Aging (Albany NY). – 2020. – Vol. 12. – P. 6049-6057. URL: https://doi.org/10.18632/aging.103000.
6. Epidemiology Working Group for Ncip Epidemic Response. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. (In Chinese)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145−151.
7. CDC. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 − United States, February 12 − March 28, 2020. MMWR. 2020;69(13):382–386.
8. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. doi: https://doi.org/10.1001/jama.2020.4683.
9. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–310. doi: https://doi.org/10.1016/j.dsx.2020.04.004
10. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395–403. doi: https://doi.org/10.1016/j.dsx.2020.04.018.
11. Ling, L., Lianfeng, L., Wei, C., Taisheng, L. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia // Emerg Microbes Infect. – 2020. – Vol. 9(1). – P. 727-732. doi: 10.1080/22221751.2020.1746199.
12. Tang, N.L., Chan, P.K., Wong, C.K. et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome // Clin Chem. – 2005. – Vol. 51. – P. 2333–2340. doi:10.1373/clinchem.2005.054460.
13. Zhang, H., Penninger, J.M., Li, Y., Zhong, N., Slutsky, A. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target // Intensive Care Med. – 2020. – Vol. 46(4). – P. 586–590. doi: 10.1007/s00134-020-05985-9.
14. Wu, Z., McGoogan, J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention // JAMA. – 2020. doi.: 10.1001/jama.2020.2648.
15. Channappanavar, R., Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin Immunopathol. – 2017. – Vol. 39. – P. 529–539. doi: 10.10 07/s0 0281-017-0629-x.
16. Huang, C., Wang, Y., Li, X., Ren, L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. – 2020. – Vol. 395(10223), Feb 15. – P. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
17. Jing, Y., Zheng, Y. Gou, X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis // Int J Infect Dis. – 2020. – Mar 12. doi:10.1016/j.ijid.2020.03.017.
18. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome // Lancet Respir Med. – 2020. – Feb 18. doi:10.1016/S2213-260 0(20)30 076-X.
19. Rabi FA, Al Zoubi MS, Kasasbeh GA, et al. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231–235. doi: https://doi.org/10.3390/pathogens9030231
20. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine. 2020 Apr;68(1):2-5. doi: 10.1007/s12020-020-02294-5. PMID: 32279224; PMCID: PMC7150529.
21. Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020;16(6):297–298. doi.org/10.1038/s41574-020- 0353-9.
22. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid 19. N Engl J Med. 2020;382(17):1653–1659. doi.org/10.1056/NEJMsr2005760.
23. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–199. doi.org/10.1007/s00592-009- 0109-4.
24. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41(2):127–133.
25. Richard C, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. BMJ Open Diabetes Res Care. 2017;5(1): e000379. doi:10.1136/bmjdrc 2016-000379.
26. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
27. Richard C, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. BMJ Open Diabetes Res Care. 2017;5(1): e000379. doi:10.1136/bmjdrc 2016-000379.
28. Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc. 2017;14(Suppl. 5):S406–S409.
29. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020. [Ahead of print, published online 9 April 2020]. doi:10.1002/ oby.22831.
30. Kravchuk E.N, Neymark A.E, Babenko A.Yu, Grineva E.N. Obesity and COVID 19. Arterial’naya Gipertenziya = Arterial Hypertension. 2020;26(4):439–445. doi:10.18705/1607-419X-2020-26-4-440-446
Опубликован
2021-03-14
Как цитировать
Хохлова А. В., Бойченко П. К., Пархомчук Д. С., Востриков А. А. Течение COVID-19 у лиц с сахарным диабетом и ожирением в кластере метаболического синдрома // Патологическая физиология и экспериментальная терапия. 2021. Т. 65. № 1. С. 102–106.
Выпуск
Раздел
Обзоры
